Erythromycin stearate: Discontinuation
The supplier of erythromycin stearate tablets has informed us they are discontinuing supply of this medicine.
Reason for this discontinuation
This is due to ongoing supply challenges and having been unable to source an alternative supply.
Supplies of the 250 mg tablet (p/code 205273) are now exhausted.
Supplies of the 500 mg tablet (p/code 205311) are expected to be exhausted in November.
We will be delisting these medicines on 1 April 2022 to allow for any stock in the supply chain to be used.
We ask that you do not start any new patients on erythromycin stearate tablets.
Erythromycin stearate is not fully-funded. There are a range of other fully-funded macrolide antibiotics available.
Who to contact
If you have any further questions about this discontinuation, contact us on 0800 66 00 50 or email email@example.com